



FallTech Conference 2017



Monday, November 6, 2017

USP Workshop (*separate registration*)

7:00 a.m. – 5:30 p.m.	2017 Fall Technical Conference Registration - Grand Ballroom Foyer
8:30 a.m. – 8:45 a.m.	Welcome and Introduction – Salon A-C
8:45 a.m. – 9:30 a.m.	Analytical Procedure Lifecycle and Statistics: Applied to Analytical Procedures/General Chapters
9:30 a.m. – 10:15 a.m.	Elemental Impurities
10:15 a.m. – 10:30 a.m.	Networking Refreshment Break - Grand Ballroom Foyer
10:30 a.m. – 11:15 a.m.	USP Workshop Continues
10:30 a.m. – 11:15 a.m.	Closing Remarks
11:30 a.m.	Workshop Concludes

Monday, November 6, 2017

2017 AAM Fall Technical Conference - Day 1

- 7:00 a.m. – 5:00 p.m. **2017 Fall Technical Conference Registration** - Grand Ballroom Foyer
- 11:30 a.m. – 1:00 p.m. **Networking Welcome Lunch** – White Oak
- 1:00 p.m. – 1:15 p.m. **Welcome and Introductions**
David Gaugh, RPh
Senior Vice President, Sciences & Regulatory Affairs, AAM
- 1:15 p.m. – 1:45 p.m. **State of AAM Address**
Chester “Chip” Davis, Jr., JD
President and CEO, AAM
- 1:45 p.m. – 2:30 p.m. **State of OGD Address**
Kathleen Uhl, PhD
Director, Office of Generic Drugs (OGD), FDA
- 2:30 p.m. – 3:00 p.m. **Networking Refreshment Break** - Grand Ballroom Foyer
- 3:00 p.m. – 3:30 p.m. **FDA Commissioner Keynote Address**
Scott Gottlieb, MD
Commissioner, FDA
- 3:30 p.m. – 4:00 p.m. **State of OPQ Address**
Giuseppe Randazzo, MS
Director, Office of Program and Regulatory Operations (OPRO)
Office of Pharmaceutical Quality (OPQ), FDA
- 4:00 p.m. – 4:30 p.m. **State of ORA Address**
Erika Anderson, JD, MPA
Deputy Associate Commissioner for Regulatory Affairs (Acting), FDA
- 4:30 pm – 5:30 pm **International Harmonization – IGBA Perspective**
Moderator: **David, Gaugh, RPh**
Senior Vice President, Sciences & Regulatory Affairs, AAM
Nicholas Cappuccino, Jr., PhD
Vice-President, Head of Quality and Scientific Affairs
Dr. Reddy’s Laboratories, Inc.
Chair, Science Committee IGBA
Sergio Napolitano, LLM
Legal and External Relations Director
Medicines for Europe
- 5:30 p.m. – 7:00 p.m. **Networking Welcome Reception** - Grand Ballroom Foyer

Tuesday, November 7, 2017

2017 AAM Fall Technical Conference - Day 2

- 7:00 a.m. – 8:00 a.m. **Networking Breakfast** – Salon A-C
- 8:00 a.m. – 9:00 a.m. **Rising Drug Prices: Opportunities for Generics**
Speaker(s) TBD
- 9:00 a.m. – 10:00 a.m. **GDUFA II Pre – ANDA Program**
Moderator: Kiran Krishnan, PhD
Senior Vice President, US Regulatory Affairs, Apotex, Inc.
Robert Lionberger, PhD
Director, Office of Research Standards (ORS), OGD, FDA
Kris Andre, MS (panelist)
Senior Regulatory Project Manager, ORS, OGD, FDA
- 10:00 a.m. – 10:30 a.m. **Networking Refreshment Break** - Grand Ballroom Foyer
- 10:30 a.m. – 12:00 p.m. **Office of Generic Drugs GDUFA II Review Program**
Enhancements (Part I)
Moderator: Scott Tomsky, MS, BS
Vice President, Regulatory Affairs, Generics North America
Teva Pharmaceuticals
Kwadwo (Kojo) Awuah, PharmD
Team Leader, Division of Filing, Office of Regulatory Operations (ORO)
OGD, FDA
Nicholas Daniel, PharmD
Regulatory Project Manager, DPM, ORO, OGD, FDA
Michael Folkendt, MS
Associate Director for Regulatory Affairs, OPRO, OPQ, FDA
Tiffany Houser, PharmD
Regulatory Project Manager, Division of Project Management (DPM),
ORO, OGD, FDA
LCDR Andrew Kim, PharmD
Supervisory Project Manager, DPM, ORO, OGD, FDA
Heidi Lee, PharmD
Project Manager, Immediate Office (IO), ORO, OGD, FDA
CDR Vincent Sansone, PharmD, CPH
Deputy Director (Acting), ORO, OGD, FDA
Priya Shah, PharmD
Project Manager, IO, ORO, OGD, FDA
Edward Sherwood, BA
Director, ORO, OGD, FDA
- 12:00 p.m. – 1:30 p.m. **Fall Technical Conference Luncheon** - White Oak

1:30 p.m. – 3:30 p.m.

Office of Generic Drugs GDUFA II Review Program Enhancements (Part II)

Moderator: Scott Tomsky, MS, BS

Vice President, Regulatory Affairs, Generics North America
Teva Pharmaceuticals

Kwadwo (Kojo) Awuah, PharmD

Team Leader, Division of Filing, Office of Regulatory Operations (ORO)
OGD, FDA

Nicholas Daniel, PharmD

Regulatory Project Manager, DPM, ORO, OGD, FDA

Michael Folkendt, MS

Associate Director for Regulatory Affairs, OPRO, OPQ, FDA

Tiffany Houser, PharmD

Regulatory Project Manager, Division of Project Management (DPM),
ORO, OGD, FDA

LCDR Andrew Kim, PharmD

Supervisory Project Manager, DPM, ORO, OGD, FDA

Heidi Lee, PharmD

Project Manager, Immediate Office (IO), ORO, OGD, FDA

CDR Vincent Sansone, PharmD, CPH

Deputy Director (Acting), ORO, OGD, FDA

Priya Shah, PharmD

Project Manager, IO, ORO, OGD, FDA

Edward Sherwood, BA

Director, ORO, OGD, FDA

3:30 p.m. – 4:00 p.m.

Networking Refreshment Break - Grand Ballroom Foyer

4:00 p.m. – 6:00 p.m.

Expo Session

FDA Booths:

- Office of Management
- Drug Shortage Team
- Office of Compliance (invited)
- Office of Regulatory Affairs (invited)

Industry Booths:

- Association for Accessible Medicines
- Pragmatic QbD for Generic Drug Development
- Operating Under GDUFA II
- From Bench to Bedside: A Sponsor's Perspective of the Journey of a Generic Drug
- Benefits of Harmonized Post-Approval Changes
- Industry Timeline for Responses: CRLs, DRLs, IRs
- Greater Transparency from FDA: Forfeiture Decisions – Greater Predictability and On Time Launches

Expo Participants:

Germain Bryant, MA, Management Analyst, Facilities Team, Generics Branch, Division of User Fee Management & Budget Formulation, OM, FDA

CAPT Christine Bina, RPh, MPH, Team Leader, Drug Storage Staff, FDA

Amy Byrom, Associate Director, Regulatory Affairs Sandoz Inc.

Mitul Chatterjee, Assistant Vice President, CMC Regulatory Affairs, Amneal Pharmaceuticals

Sandra D'Agostino-Ferlisi, Associate Director Regulatory Affairs Intelligence and Training, Apotex Inc.

Pramod Dahibate, Vice President, Regulatory, Lupin Ltd.

Joyce Delgaudio, Executive Director, Regulatory Affairs Teva Pharmaceuticals

Candis Edwards, Senior Vice President, Clinical Regulatory Affairs, Amneal Pharmaceuticals

Cheryl Hawkins, Management Analyst, Division of User Fee Management & Budget Formulation, OM, FDA

Richard Holl, PhD, Director, Development Operations, Lupin Research Inc.

Evelyn Hong, PharmD, Program Manager, Division of User Fee Management and Budget Formulation, OM, FDA

Sudhir Kaushal, MPharm, Director, Regulatory Affairs, Lupin Pharmaceutical Inc.

John Kennedy, Manager, Regulatory Affairs, Sandoz Inc.

Maria Kim, DPT, Project Manager, Generics Branch, Division of User Fee Management & Budget Formulation, OM, FDA

Pavan Kumar, Director, CMC Regulatory Affairs, Amneal Pharmaceuticals

Michelle Lee-Bourner, Head Global Respiratory Regulatory, Regulatory Affairs, Mylan Inc.

Brian McCormick, General Counsel, Regulatory and Lifecycle, Teva Pharmaceuticals

Anna McDermott-Vitak, Senior Vice President, Corporate Development and Administration, AAM

Scott McGuinness, Regulatory Affairs Association III, Sandoz Inc.

Dattatraya (Datta) Nagargoje, General Manager, Regulatory Affairs, Mylan Inc.

Martina O'Sullivan, Head of Global Regulatory Affairs (Injectables), Mylan Inc.

Jill Pastore, Senior Director, Regulatory Affairs, Teva Pharmaceuticals

Alpesh Patel, Vice President, CMC Regulatory Affairs, Amneal Pharmaceuticals

Priyanka Pawar, Assistant Vice President, CMC Regulatory Affairs, Amneal Pharmaceuticals

Giseuda "Gisa" Perez, MBA, Generics Branch Chief, Division of User Fee Management and Budget Formulation, OM, FDA

Hanah Pham, PharmD, Facilities Team Lead, Generics Branch, Division of User Fee Management and Budget Formulation OM, FDA

Jyoti Sachdeva, PhD, Senior Director, Regulatory Affairs, Mylan Inc.

Greg Seitz, Director, Regulatory Affairs, Sandoz Inc.

Jewel Smith, Director, Operations, AAM

Olivia Souweine, Med, Management Analyst, Applications Team, Generics Branch, Division of User Fee Management and Budget Formulation, OM, FDA

Aloka Srinivasan, PhD, Vice President, Regulatory Affairs, Lupin Pharmaceutical Inc.

Santhanakrishnan Srinivasan, Senior Director, Project Management and Complex Product Development Amneal Pharmaceuticals

Adam Steinberg, PharmD, Regulatory Project Manager, US Regulatory Affairs, Apotex Inc.

Meghal Vakil, Regulatory Project Manager, Apotex Inc.


Janet Vaughn, Senior Director, Regulatory Affairs, Teva Pharmaceuticals

Katherine (Katie) Wilson, Director, Global Regulatory Affairs Policy, Mylan Inc.

CDR Leo Zadecky, RPh, Senior Program Officer, Drug Storage Staff, FDA

From Bench to Bedside: A Sponsor's

Perspective of the Journey of a Generic Drug



6:00 p.m. – 6:30 p.m. **Networking Reception** - Grand Ballroom Foyer

6:30 p.m. – 9:00 p.m. **AAM Lip Sync Battle Dinner and Entertainment**

Wednesday, November 8, 2017

2017 AAM Fall Technical Conference - Day 3

7:30 a.m. – 8:30 a.m. **Networking Breakfast** – Salon A-C / White Oak

8:30 a.m. – 9:30 a.m. **Anatomy of an Expedited/Priority Review**

Moderator: **Robert Pollock**

Senior Advisor, Outside Director to the Board
Lachman Consultants Services, Inc.

Kurt Karst, JD

Director, Hyman, Phelps & McNamara, P.C.

Scott Tomskey, MS, BS

Vice President, Regulatory Affairs, Generics North America
Teva Pharmaceuticals

9:30 a.m. – 11:00 a.m. **Data Integrity Issues in Today's Complex and Global Manufacturing Supply Chain**

Moderator: **Derek Glover**

Head of Global Quality Systems and Compliance
Mylan Pharmaceuticals Inc.

Derek Smith, PhD

Branch Chief (Acting), Division of Inspectional Assessment
Office of Process and Facility (OPF), OPQ, FDA

Frances Zipp

President, Lachman Consultant Services, Inc.

LCDR Mahesh Ramanadham, PharmD, MBA, RPh (panelist)

Director (Acting), Division of Inspectional Assessment
OPF, OPQ FDA

11:00 a.m. – 11:30 a.m. **Networking Refreshment Break** - Grand Ballroom Foyer

11:30 a.m. – 12:00 p.m. **Update – Implementation of GDUFA II User Fees**

Moderator: **Candis Edwards**

Senior Vice President, Regulatory Affairs, Amneal Pharmaceuticals
Donal Parks, MBA, MPM

Director, Division of User Fee Management and Budget Formulation,
Office of Management, FDA

12:00 p.m. – 1:30 p.m. **Fall Technical Conference Luncheon** - Salon A-B / White Oak

1:30 p.m. – 2:30 p.m.

Fall Technical Conference Breakout Sessions

Excipients – Standards for Pharmaceutical Products Salon D-E	The Path to Bioequivalence - Great Progress, Great Opportunities Salon C	Complexity of Retention Samples Selection in Non-Traditional Bioequivalence Studies White Flint Amphitheater (lower-level)
<p>Moderator: Ravi Harapanhalli, PhD Senior Vice President Global Regulatory Affairs Amneal Pharmaceuticals</p> <p>USP Speaker(s) TBD</p>	<p>Moderator: Kiran Krishnan, PhD Senior Vice President US Regulatory Affairs, Apotex, Inc.</p> <p>Charles DiLiberti President Montclair Bioequivalence Services, LLC</p>	<p>Moderator: Siva Vaithiyalingam, PhD Vice President, Regulatory Affairs North America, Cipla LTD</p> <p>Nageshwar Thudi, PhD Director, Clinical Research and Development, Teva Pharm</p>

2:30 p.m. – 3:00 p.m.

Networking Refreshment Break - Grand Ballroom Foyer

3:00 p.m. – 4:00 p.m.

Fall Technical Conference Breakout Sessions

Stability Guidance +3 Years: Where Are We Now? Salon D-E	Drug Product Quality and the Impact of Extractables and Leachables Salon C
<p>Moderator: Molly Rapp Vice President, Regulatory Affairs US Innovation and Development, Generics and Standard Solutions, Fresenius Kabi USA LLC</p> <p>Marcy Macdonald, RAC Vice President, Regulatory Affairs Impax Laboratories</p>	<p>Moderator: Dominique Kendrick, RPh, MBA, RAC President, EverestGreen Partners, Inc.</p> <p>Diane Paskiet, MS Senior Director, Global Scientific Affairs West Pharmaceuticals</p> <p>Andrea Redd, BS Director, US Regulatory Affairs Fresenius Kabi USA, LLC</p>

4:00 p.m.

Conference Concludes